|
SAR245408; XL-147
|
XL147
|
956958-53-5
|
|
GSK-163090
|
GSK163090
|
844903-58-8
|
|
ETP-46321
|
CS-2500
|
1252594-99-2
|
|
THZ1
|
THZ1
|
1604810-83-4
|
|
3-nitro-4-((tetrahydro-2H-pyran-4-yl)MethylaMino)benzenesulfonaMide
|
ABT199 中間體
|
1228779-96-1
|
|
EPZ-015666;GSK3235025;GSK-3235025;EPZ-015666
|
EPZ015666
|
1616391-65-1
|
|
Lasmiditan hemisuccinate
|
琥珀酸拉斯米迪坦
|
439239-92-6
|
|
Grapiprant
|
GRAPIPRANT
|
415903-37-6
|
|
GSK-3326595;EPZ-015938
|
GSK-3326595
|
1616392-22-3
|
|
Lasmiditan hydrochloride
|
613677-28-4
|
613677-28-4
|
|
AZD7986
|
AZD7986
|
1802148-05-5
|
|
T0901317
|
N-(2,2,2-三氟乙基)-N-[4-[2,2,2-三氟-1-羥基-1-(三氟甲基)乙基]苯基]苯磺酰胺
|
293754-55-9
|
|
LY294002;LY-294002
|
LY294002/PI3K抑制劑
|
154447-36-6
|
|
Liproxstatin-1
|
利普司他丁-1
|
950455-15-9
|
|
Fevipiprant
|
非韋匹侖
|
872365-14-5
|
|
CPI-637
|
(R)-4-甲基-6-(1-甲基-3-(1-甲基-1H-吡唑-4-基)-1H-吲唑-5-基)-4,5-二氫-1H-苯并[B][1,4]二氮雜-2(3H)-酮
|
1884712-47-3
|
|
Acebilustat
|
阿西魯司特
|
943764-99-6
|
|
UK-371804; Urokinase inhitibor 1
|
化合物UK371804
|
256477-09-5
|
|
NCB-0846
|
NCB-0846
|
1792999-26-8
|
|
4-bromo-2-methoxyaniline
|
4-溴-2-甲氧基苯胺
|
59557-91-4
|
|
Icotinib hydrochloride
|
Icotinib hydrochloride; 埃克替尼鹽酸鹽
|
1204313-51-8
|
|
HTH-01-015
|
HTH-01-015
|
1613724-42-7
|
|
UNC2025
|
反式-4-[2-(丁基氨基)-5-[4-[(4-甲基-1-哌嗪基)甲基]苯基]-7H-吡咯并[2,3-D]嘧啶-7-基]-環(huán)己醇
|
1429881-91-3
|
|
Mivebresib; ABBV-075
|
米維布塞
|
1445993-26-9
|
|
Pexidartinib
|
N/A
|
1029044-16-3
|
|
NCGC00244536
|
3-(8-羥基喹啉-6-基)-N-(3-苯基丙基)苯甲酰胺
|
2003260-55-5
|
|
Emapunil; AC-5216
|
AC-5216
|
226954-04-7
|
|
Galeterone
|
Galeterone
|
851983-85-2
|
|
SRT-2104
|
1093403-33-8
|
|
AMG-319
|
AMG319
|
1608125-21-8
|
|
CC-223
|
CC-223
|
1228013-30-6
|
|
GSK591; EPZ-015866
|
GSK591 (EPZ-015866)
|
1616391-87-7
|
|
BDA-366
|
1-[[(2S)-3-(二乙基氨基)-2-羥基丙基]氨基]-4-[[(2S)-2-環(huán)氧乙烷基甲基]氨基]-9,10-蒽醌
|
1909226-00-1
|
|
SKF-86002
|
6-(4-氟苯基)-5-(4-吡啶基)-2,3-二氫咪唑并[2,1-B]-噻唑
|
72873-74-6
|
|
6-bromo-[1,2,4]triazolo[1,5-a]pyridine
|
6-溴-[1,2,4]三唑并[1,5-a]吡啶
|
356560-80-0
|
|
Motolimod; VTX-2337
|
MOTOLIMOD
|
926927-61-9
|
|
AC-710
|
N-[4-[[[[5-(叔丁基)-3-異惡唑基]氨基]羰基]氨基]苯基]-5-[(1-乙基-2,2,6,6-四甲基-4-哌啶基)氧基]-2-吡啶甲酰胺
|
1351522-04-7
|
|
EW-7197
|
EW-7197
|
1352608-82-2
|
|
Q203
|
Q203
|
1334719-95-7
|
|
OICR-9429
|
OICR-9429
|
1801787-56-3
|
|
Ticagrelor
|
替卡格雷，替格雷洛，替格瑞洛
|
274693-27-5
|
|
Vipadenant; BIIB 014
|
3-(4-氨基-3-甲基芐基)-7-(呋喃-2-基)-3H-[1,2,3]三唑并[4,5-D]嘧啶-5-胺
|
442908-10-3
|
|
CEP-33779
|
N-[3-(4-甲基-1-哌嗪基)苯基]-8-[4-(甲磺酰基)苯基]-[1,2,4]三唑并[1,5-A]吡啶-2-胺
|
1257704-57-6
|
|
GSK-189254A
|
6-(3-CYCLOBUTYL-2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPIN-7-YLOXY)-N-METHYLNICOTINAMIDE
|
720690-73-3
|
|
Ponatinib-HCl; AP24534-HCl
|
普納替尼鹽酸鹽；普納替尼單鹽酸鹽
|
1114544-31-8
|
|
RGB-286638
|
N-[1,4-二氫-3-[4-[[4-(2-甲氧基乙基)-1-哌嗪基]甲基]苯基]-4-氧代茚并[1,2-C]吡唑-5-基]-N'-4-嗎啉基脲
|
784210-88-4
|
|
TAK-632; TAK-0632
|
TAK-632
|
1228591-30-7
|
|
MK-4827 tosylate; Niraparib tosylate
|
MK-4827 tosylate; Niraparib tosylate; Niraparib對甲苯磺酸鹽; MK-4827 對甲苯磺酸鹽
|
1038915-73-9
|
|
SUN11602; SUN-11602
|
化合物SUN 11602
|
704869-38-5
|
|
MCC-950 Sodium
|
MCC950
|
210826-40-7
|
|
All-rac-alfa-TocopherolEP impurity C
|
生育酚雜質(zhì)C
|
10191-41-0
|
|
AG-221; Enasidenib
|
恩西地平
|
1446502-11-9
|
|
GSK2982772
|
GSK2982772
|
1622848-92-3
|
|
(6-aminopyridin-2-yl)(1-methylpiperidin-4-yl)methanone hydrogen bromide
|
LASMIDITAN 中間體
|
1338000-32-0
|
|
CHIR-090
|
CHIR 090
|
728865-23-4
|
|
PFI-3
|
(2E)-1-(2-羥基苯基)-3-[(1R,4R)-5-(2-吡啶基)-2,5-二氮雜雙環(huán)[2.2.1]庚-2-基]-2-丙烯-1-酮
|
1819363-80-8
|
|
MS023; MS-023
|
N1-甲基-N1-[[4-[4-(異丙氧基)苯基]-1H-吡咯-3-基]甲基]-1,2-乙二胺
|
1831110-54-3
|
|
MK-4101
|
5-(3,3-二氟環(huán)丁基)-3-[4-[4-甲基-5-[2-(三氟甲基)苯基]-4H-1,2,4-三唑-3-基]雙環(huán)[2.2.2]辛烷-1-基]-1,2,4-惡二唑
|
935273-79-3
|
|
RAF-709
|
化合物RAF709
|
1628838-42-5
|
|
NVS-PAK1-1
|
NVS-PAK1-1
|
1783816-74-9
|
|
1-methyl-3-amino-4-cyanopyrazole
|
1-甲基-3-胺基-4-氰基吡唑
|
21230-50-2
|
|
Lasmiditan
|
拉米地坦
|
439239-90-4
|
|
BX-471; ZK-811752
|
(R)-1-(5-氯-2-(2-(4-(4-氟芐基)-2-甲基哌嗪-1-基)-2-氧代乙氧基)苯基)脲
|
217645-70-0
|
|
UNC1215
|
UNC1215
|
1415800-43-9
|
|
Pilaralisib; XL147
|
2-氨基-N-[3-[N-[3-[(2-氯-5-甲氧基苯基)氨基]喹喔啉-2-基]氨基磺?；鵠苯基]-2-甲基丙酰胺
|
934526-89-3
|
|
CWHM-12
|
CWHM-12
|
1564286-55-0
|
|
Defactinib hydrochloride; VS-6063; PF-04554878
|
PF-04554878
|
1073160-26-5
|
|
ML324
|
ML324
|
1222800-79-4
|
|
GBT-440
|
沃塞洛托
|
1446321-46-5
|
|
BAY-876
|
BAY-876
|
1799753-84-6
|
|
SH5-07; SH-5-07
|
1456632-41-9
|
1456632-41-9
|
|
AMG-3969
|
AMG-3969
|
1361224-53-4
|
|
2-(2-chloro-6-morpholino-9H-purin-8-yl)propan-2-ol
|
2-(2-氯-6-嗎啉代-9H-嘌呤-8-基)丙-2-醇
|
1198171-62-8
|
|
SD-208
|
SD-208
|
627536-09-8
|
|
MK-1775
|
MK-1775
|
955365-80-7
|
|
AC 55541
|
AC-55541
|
916170-19-9
|
|
MK-8776
|
SCH-900776
|
891494-64-7
|
|
Binimetinib; MEK-162; ARRY-162;ARRY-438162
|
貝美替尼
|
606143-89-9
|
|
Defactinib: VS-6063: PF-04554878
|
地法替尼
|
1073154-85-4
|
|
E 7449; E-7449
|
E7449
|
1140964-99-3
|
|
GSK-2256098
|
GSK-2256098
|
1224887-10-8
|
|
CP-21R7
|
GSK-3Β抑制劑(CP21R7)
|
125314-13-8
|
|
Coelenterazine
|
腔腸素
|
55779-48-1
|
|
CP-609754 (OSI754)
|
CP-609754
|
1190094-64-4
|
|
GS-9620
|
GS9620
|
1228585-88-3
|
|
XMD8-87
|
5,11-二氫-2-((2-甲氧基-4-(4-甲基-1-哌嗪基)苯基)氨基)-11-甲基-6H-嘧啶并[4,5-B][1,4]苯并二氮雜卓-6-酮
|
1234480-46-6
|
|
SH-4-54
|
SH-4-54
|
1456632-40-8
|
|
BP-1-102
|
4-(N-(4-環(huán)己基芐基)-2-((2,3,4,5,6-五氟-N-甲苯基)磺酰氨基)乙酰氨基)-2-羥基苯甲酸
|
1334493-07-0
|
|
ABT-639
|
ABT-639
|
1235560-28-7
|
|
GDC-0084; GDC 0084
|
GDC-0084
|
1382979-44-3
|
|
GNE-3511
|
化合物GNE-3511
|
1496581-76-0
|
|
XMD16-5
|
2-((4-(4-羥基哌啶-1-基)苯基)氨基)-11-甲基-5H-苯并[E]嘧啶并[5,4-B][1,4]二氮雜卓-6(11H)-酮
|
1345098-78-3
|
|
STK16-IN-1
|
化合物STK16-IN-1
|
1223001-53-3
|